

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4250809

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT		
EFFECTIVE DATE:	12/16/2016		
CONVEYING PARTY DATA			
Name			Execution Date
ESSENTIAL PHARMACEUTICALS, LLC			12/19/2016
RECEIVING PARTY DATA			
Name:	BIO-ESS LABORATORIES, LLC		
Street Address:	100 PRINCETON SOUTH CORPORATE CENTER		
Internal Address:	1ST FLOOR, SUITE 140		
City:	EWING		
State/Country:	NEW JERSEY		
Postal Code:	08628		
PROPERTY NUMBERS Total: 2			
Property Type	Number		
Application Number:	13673739		
Application Number:	14577414		
CORRESPONDENCE DATA			
Fax Number:	(312)474-0448		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	anagelberg@marshallip.com		
Correspondent Name:	MARSHALL, GERSTEIN & BORUN LLP		
Address Line 1:	233 SOUTH WACKER DRIVE		
Address Line 2:	SUITE 6300		
Address Line 4:	CHICAGO, ILLINOIS 60606		
ATTORNEY DOCKET NUMBER:	31679/46272A, 47561		
NAME OF SUBMITTER:	AUDREY NAGELBERG		
SIGNATURE:	/Audrey Nagelberg/		
DATE SIGNED:	01/31/2017		
Total Attachments: 8			
source=essential patent assign#page1.tif			
source=essential patent assign#page2.tif			
source=essential patent assign#page3.tif			

source=essential patent assign#page4.tif
source=essential patent assign#page5.tif
source=essential patent assign#page6.tif
source=essential patent assign#page7.tif
source=essential patent assign#page8.tif

PATENT ASSIGNMENT

This Patent Assignment (the "Assignment") is made by and between Essential Pharmaceuticals, LLC, a Delaware limited liability company ("Assignor"), and Bio-Ess Laboratories, LLC, a Delaware limited liability company ("Assignee").

WHEREAS, Assignor and Assignee are parties to a certain Contribution Agreement effective as of December 16, 2016 (the "Agreement"); and

WHEREAS, pursuant to the Agreement, Assignor agreed to assign to Assignee certain of Assignor's assets, which include the patents and patent applications in Exhibit A ("Patents").

NOW THEREFORE, for good and valuable consideration, the receipt and legal sufficiency of which is hereby acknowledged, Assignor hereby, without reservation:

1. Irrevocably sells, assigns and transfers to Assignee, its successors and assigns its entire right, title and interest, both legal and equitable, throughout the world, in and to the Patents, as well all provisionals, continuations, continuations-in-part, and divisionals claiming priority thereto, all patents issuing therefrom, including all rights of priority, any reexaminations and reissues, as well as extensions of or supplementary protection certificates on any of the foregoing (the "Patent Rights"). This Assignment includes any rights of Assignee to sue for and retain damages for past, present and future infringement and seek other remedies for infringement of the Patent Rights.
2. Authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any similar office anywhere in the world, to issue or transfer all the Patent Rights to Assignee, as assignee of the entire right, title, and interest therein or otherwise as Assignee may direct.

[Signature Page Follows.]

SCHEDULE A

Client No.	Matter No.	Country	Inventor	Title	Appl. No.	Filed
31679	46272A	Australia	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	2012335070	09-Nov-12
31679	46272A	Brazil	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	BR112014011414-5	09-Nov-12
31679	46272A	Canada	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	2854780	09-Nov-12
31679	46272A	Chile	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	01181-2014	09-Nov-12
31679	46272A	China	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	201280057698.X	09-Nov-12
31679	46272A	Eurasian Patent Office	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	201490945	09-Nov-12
31679	46272A	European Patent Office	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	12847737.9	09-Nov-12
31679	46272A	Hong Kong	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	15102719.9	09-Nov-12
31679	46272A	India	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	4264/CHENP/2014	09-Nov-12
31679	46272A	Indonesia	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	P00201403426	09-Nov-12
31679	46272A	Israel	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	232446	09-Nov-12
31679	46272A	Japan	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	2014-541340	09-Nov-12
31679	46272A	Malaysia	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	PI2014001363	09-Nov-12
31679	46272A	Mexico	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	MX/a/2014/005723	09-Nov-12
31679	46272A	New Zealand	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	624616	09-Nov-12
31679	46272A	Philippines	Elhofy et al.	Kit Comprising Serum Replacement And	1-2014-501019	09-Nov-12

Client No.	Matter No.	Country	Inventor	Title	Appl. No.	Filed
				Labile Factors		
31679	46272A	Singapore	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	11201402108Y	09-Nov-12
31679	46272A	South Africa	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	2014/03352	09-Nov-12
31679	46272A	South Korea	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	10-2014-7015315	09-Nov-12
31679	46272A	United States	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	13/673739	09-Nov-12
31679	46272A	Vietnam	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	1-2014-01917	09-Nov-12
31679	47561	Argentina	Elhofy et al.	Media for Cell Culture	P140104810	19-Dec-14
31679	47561	Australia	Elhofy et al.	Media for Cell Culture	2014364368	19-Dec-14
31679	47561	Brazil	Elhofy et al.	Media for Cell Culture	BR112016014488-0	19-Dec-14
31679	47561	Canada	Elhofy et al.	Media for Cell Culture	2934487	19-Dec-14
31679	47561	Chile	Elhofy et al.	Media for Cell Culture	201601553	19-Dec-14
31679	47561	China	Elhofy et al.	Media for Cell Culture	201480075947.7	19-Dec-14
31679	47561	Eurasian Patent Office	Elhofy et al.	Media for Cell Culture	201691297	19-Dec-14
31679	47561	European Patent Office	Elhofy et al.	Media for Cell Culture	14870754.0	19-Dec-14
31679	47561	India	Elhofy et al.	Media for Cell Culture	201647023899	19-Dec-14
31679	47561	Israel	Elhofy et al.	Media for Cell Culture	246262	19-Dec-14
31679	47561	Japan	Elhofy et al.	Media for Cell Culture	2016-560860	19-Dec-14
31679	47561	Malaysia	Elhofy et al.	Media for Cell Culture	PI2016001140	19-Dec-14
31679	47561	Mexico	Elhofy et al.	Media for Cell Culture	MX/a/2016/008251	19-Dec-14
31679	47561	Singapore	Elhofy et al.	Media for Cell Culture	11201604994U	19-Dec-14
31679	47561	South Korea	Elhofy et al.	Media for Cell Culture	10-2016-7019241	19-Dec-14
31679	47561	Taiwan	Elhofy et al.	Media for Cell Culture	103144675	19-Dec-14
31679	47561	United States	Elhofy et al.	Media for Cell Culture	14/577414	19-Dec-14

PATENT ASSIGNMENT

This Patent Assignment (the "Assignment") is made by and between Essential Pharmaceuticals, LLC, a Delaware limited liability company ("Assignor"), and Bio-Ess Laboratories, LLC, a Delaware limited liability company ("Assignee").

WHEREAS, Assignor and Assignee are parties to a certain Contribution Agreement effective as of December 16, 2016 (the "Agreement"); and

WHEREAS, pursuant to the Agreement, Assignor agreed to assign to Assignee certain of Assignor's assets, which include the patents and patent applications in Exhibit A ("Patents").

NOW THEREFORE, for good and valuable consideration, the receipt and legal sufficiency of which is hereby acknowledged, Assignor hereby, without reservation:

1. Irrevocably sells, assigns and transfers to Assignee, its successors and assigns its entire right, title and interest, both legal and equitable, throughout the world, in and to the Patents, as well all provisionals, continuations, continuations-in-part, and divisionals claiming priority thereto, all patents issuing therefrom, including all rights of priority, any reexaminations and reissues, as well as extensions of or supplementary protection certificates on any of the foregoing (the "Patent Rights"). This Assignment includes any rights of Assignee to sue for and retain damages for past, present and future infringement and seek other remedies for infringement of the Patent Rights.
2. Authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any similar office anywhere in the world, to issue or transfer all the Patent Rights to Assignee, as assignee of the entire right, title, and interest therein or otherwise as Assignee may direct.

[Signature Page Follows.]

SCHEDULE A

Client No.	Matter No.	Country	Inventor	Title	Appl. No.	Filed
31679	46272A	Australia	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	2012335070	09-Nov-12
31679	46272A	Brazil	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	BR112014011414-5	09-Nov-12
31679	46272A	Canada	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	2854780	09-Nov-12
31679	46272A	Chile	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	01181-2014	09-Nov-12
31679	46272A	China	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	201280057698.X	09-Nov-12
31679	46272A	Eurasian Patent Office	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	201490945	09-Nov-12
31679	46272A	European Patent Office	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	12847737.9	09-Nov-12
31679	46272A	Hong Kong	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	15102719.9	09-Nov-12
31679	46272A	India	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	4264/CHENP/2014	09-Nov-12
31679	46272A	Indonesia	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	P00201403426	09-Nov-12
31679	46272A	Israel	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	232446	09-Nov-12
31679	46272A	Japan	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	2014-541340	09-Nov-12
31679	46272A	Malaysia	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	PI2014001363	09-Nov-12
31679	46272A	Mexico	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	MX/a/2014/005723	09-Nov-12
31679	46272A	New Zealand	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	624616	09-Nov-12
31679	46272A	Philippines	Elhofy et al.	Kit Comprising Serum Replacement And	1-2014-501019	09-Nov-12

Client No.	Matter No.	Country	Inventor	Title	Appl. No.	Filed
				Labile Factors		
31679	46272A	Singapore	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	11201402108Y	09-Nov-12
31679	46272A	South Africa	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	2014/03352	09-Nov-12
31679	46272A	South Korea	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	10-2014-7015315	09-Nov-12
31679	46272A	United States	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	13/673739	09-Nov-12
31679	46272A	Vietnam	Elhofy et al.	Kit Comprising Serum Replacement And Labile Factors	1-2014-01917	09-Nov-12
31679	47561	Argentina	Elhofy et al.	Media for Cell Culture	P140104810	19-Dec-14
31679	47561	Australia	Elhofy et al.	Media for Cell Culture	2014364368	19-Dec-14
31679	47561	Brazil	Elhofy et al.	Media for Cell Culture	BR112016014488-0	19-Dec-14
31679	47561	Canada	Elhofy et al.	Media for Cell Culture	2934487	19-Dec-14
31679	47561	Chile	Elhofy et al.	Media for Cell Culture	201601553	19-Dec-14
31679	47561	China	Elhofy et al.	Media for Cell Culture	201480075947.7	19-Dec-14
31679	47561	Eurasian Patent Office	Elhofy et al.	Media for Cell Culture	201691297	19-Dec-14
31679	47561	European Patent Office	Elhofy et al.	Media for Cell Culture	14870754.0	19-Dec-14
31679	47561	India	Elhofy et al.	Media for Cell Culture	201647023899	19-Dec-14
31679	47561	Israel	Elhofy et al.	Media for Cell Culture	246262	19-Dec-14
31679	47561	Japan	Elhofy et al.	Media for Cell Culture	2016-560860	19-Dec-14
31679	47561	Malaysia	Elhofy et al.	Media for Cell Culture	PI2016001140	19-Dec-14
31679	47561	Mexico	Elhofy et al.	Media for Cell Culture	MX/a/2016/008251	19-Dec-14
31679	47561	Singapore	Elhofy et al.	Media for Cell Culture	11201604994U	19-Dec-14
31679	47561	South Korea	Elhofy et al.	Media for Cell Culture	10-2016-7019241	19-Dec-14
31679	47561	Taiwan	Elhofy et al.	Media for Cell Culture	103144675	19-Dec-14
31679	47561	United States	Elhofy et al.	Media for Cell Culture	14/577414	19-Dec-14